The Changing Landscape of Urothelial Carcinoma Therapy: Updates from ASCO GU 2023

The Changing Landscape of Urothelial Carcinoma Therapy: Updates from ASCO GU 2023

Bibliographic Details
Main Author:	Alex Friedlaender
Format:	Article
Language:	English
Published:	THE HEALTHBOOK COMPANY LTD. 2023-06-01
Series:	healthbook TIMES. Oncology Hematology
Online Access:	https://doi.org/10.36000/hbT.OH.2023.16.109

Similar Items

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
by: Jiazheng Yu, et al.
Published: (2023-07-01)

Urothelial Carcinoma Highlights from ASCO GU 2021: Ground-Breaking Studies
by: Frank Stenner
Published: (2021-06-01)

New treatments and trials for renal cell carcinoma: Latest updates from 2023 ASCO-GU Cancers Symposium
by: Yiqing Guo, et al.
Published: (2023-11-01)

Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium
by: Yuanhong Jiang, et al.
Published: (2023-08-01)

Genitourinary cancers updates: highlights from ASCO 2023
by: Qian Qin, et al.
Published: (2023-11-01)

ASCO 2023: Targeted Therapy for Early-Stage NSCLC
by: Roy Herbst
Published: (2023-06-01)

ASCO 2023: Recent Progress in Lung Cancer Therapy
by: Charu Aggarwal
Published: (2023-06-01)

CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
by: Xinyuan Liu, et al.
Published: (2023-08-01)

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
by: James F. Wu, et al.
Published: (2023-07-01)

Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
by: Olga Bodriagova, et al.
Published: (2023-09-01)

Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
by: Jiangxue Hou, et al.
Published: (2023-08-01)

Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
by: Jiangxue Hou, et al.
Published: (2023-10-01)

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
by: Juanjuan Zhao, et al.
Published: (2023-08-01)

Advancing Ovarian Cancer Treatment: The Latest Insights on PARP Inhibitors from ASCO 2023
by: Yves van Roon, et al.
Published: (2023-12-01)

New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
by: Matthieu Roulleaux-Dugage, et al.
Published: (2023-08-01)

Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update
by: Surendra S. Shastri, et al.
Published: (2022-09-01)

ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023
by: Tanja Cufer, et al.
Published: (2023-09-01)

Updates on the Pivotal Roles of Mitochondria in Urothelial Carcinoma
by: Chiang-Chi Huang, et al.
Published: (2022-10-01)

Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting
by: Jilong Yang, et al.
Published: (2022-10-01)

Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018
by: Faisal Shahjehan, et al.
Published: (2019-05-01)

Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting
by: Minghan Qiu, et al.
Published: (2022-08-01)

Repetition and distance in ASCO’s fotonovelas
by: Paloma Checa Gismero
Published: (2016-10-01)

Aktivnosti največjega mednarodnega strokovnega združenja onkologov ASCO in pogled na srečanje ASCO 2011
by: Tanja Čufer
Published: (2011-12-01)

Updates in urologic oncology guidelines: urothelial carcinoma. A review
by: Maria I. Volkova, et al.
Published: (2023-08-01)

Editorial: Therapies and influences in urothelial carcinoma
by: G. Ozgun, et al.
Published: (2022-12-01)

Changes in the treatment landscape for metastatic urothelial cancer: current therapy and future directions
by: Sang Hoon Yeon, et al.
Published: (2022-05-01)

Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma
by: Andrew B. Katims, et al.
Published: (2022-11-01)

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
by: Hong Zheng, et al.
Published: (2023-02-01)

Liquid Biopsy Landscape in Patients with Primary Upper Tract Urothelial Carcinoma
by: Stephanie N. Shishido, et al.
Published: (2022-06-01)

Zhang guo gu dai shi xue wan yan gu shi song /
by: 566562 Yan, Bei Min
Published: (1980)

The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS
by: Hyerim Ha, et al.
Published: (2022-07-01)

Combining theranostic/particle therapy with immunotherapy for the treatment of GU malignancies
by: Karin A. Skalina, et al.
Published: (2024-03-01)

Improving the accumulation of 18α-and 18β-glycyrrhizins by over-expressing GuHMGR, GuSQS1, and GuBAS genes in Glycyrrhiza uralensis
by: Rui Yang, et al.
Published: (2017-10-01)

Changshin-gu : personal ornaments
Published: (1995)

Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile
by: Mou Peng, et al.
Published: (2022-08-01)

Global Equity in Clinical Trials: An ASCO Policy Statement
by: Sana A. Al Sukhun, et al.
Published: (2024-03-01)

Interpretation on Management of Dyspnea in Advanced Cancer: ASCO Guideline
by: JIA Zhimeng, et al.
Published: (2024-01-01)

Sarcomatoid urothelial carcinoma
by: Orelvys González Otaño, et al.
Published: (2012-04-01)

The “GU-GU-RU” project to eliminate discrimination related to the health effects of the Fukushima nuclear accident
by: Isamu Amir, et al.
Published: (2023-10-01)

Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma
by: Chia-Hsien Shih, et al.
Published: (2024-03-01)